inPROBE

17/05/2024

NEW BLOG POST
🇬🇧 ® technological platform was designed to determine protein expression in a way different from the standard one. The determination is performed in vivo, directly in the patient's body, without needing to collect tissue. The result is obtained in real-time and it is quantitative, so it is an objective result, expressed in numbers. After summarizing the I part of the clinical trials, we should turn our attention to further areas of application of the breakthrough technology.
Read full article👉 https://sdsoptic.pl/en/promising-perspectives-for-the-application-of-inprobe-technology-platform-for-protein-expression-determination/

An inherent feature of modern oncology is personalization, manifested in conversion from the fit-to-all strategy based on applying the same chemotherapy regimens to all patients with a specific type of cancer to therapy tailored to the individual patient’s situation.An integral part of personaliza...

22/11/2023

08/09/2023

BMJ Journal: "the rising tide of early-onset cancers demands attention"

A new publication in the confirms the increasing number of cancer cases among people under age 50.
New cases of early-onset cancers have increased by over 79% since 1990.

Much more of the young people suffer from cancer types, which just until recently were considered typical in older age groups. These include breast, tracheal, bronchus and lung, stomach and colorectal cancers.

Scientists estimate that by 2030, the number of new cases of early cancers will increase by 31%, and at the same time the mortality rate will increase by 21%.

This is another evidence from the world of science that confirms that in addition to early diagnostics, devices such as inPROBE are essential for improve the accuracy of cancer diagnostics (detection of specific cancer molecules) and increase the targeted therapies effectiveness (drug delivery monitoring). SDS Optic 💪

ℹ️🔗 https://bmjoncology.bmj.com/content/2/1/e000049

26/06/2023

➡️We are starting technological cooperation with Philips Engineering Solutions and the CSEM research and development institute from Switzerland.
➡️ As part of the consortium created for this purpose, with SDS Optic S.A. as a leader and coordinator, we obtained funding in the amount of up to EUR 244.09 (approx. PLN 1.1 million) as part of the project, financed by the European Commission.
➡️ Our plan is to scale up, from the level of a clinical prototype to the level of a commercial and industrial prototype, the analyzer (detection device) owned by the SDS Optic, used for analyzing and measuring with disposable ® microprobes.

➡️Rozpoczynamy współpracę technologiczną z koncernem Philips Engineering Solutions oraz instytutem badawczo-rozwojowym CSEM.

➡️ W ramach utworzonego w tym celu konsorcjum, z SDS Optic S.A. w roli lidera i koordynatora, pozyskaliśmy dofinansowanie w kwocie do 244,09 EUR (ok. 1,1 mln PLN) w ramach projektu , finansowanego przez Komisję Europejską (European Commission ).

➡️ Wspólnie planujemy przeskalować, z poziomu prototypu klinicznego do poziomu prototypu komercyjnego i przemysłowego, posiadany przez Spółkę analizator (urządzenie detekcyjne), służące do analizy i pomiarów badań przy użyciu jednorazowych mikrosond inPROBE ®.

➡️ Więcej w artykule: https://sdsoptic.pl/sds-optic-s-a-rozpoczyna-wspolprace-technologiczna-z-koncernem-philipsoraz-instytutem-badawczo-rozwojowym-csem/

lub w raporcie ESPI: 🔗 https://ir.sdsoptic.com/raporty/espi-20-2023-rozpoczecie-realizacji-nowego-kamienia-milowego-przy-wspolpracy-z-philips-i-csem-oraz-pozyskanie-finansowania-w-ramach-programu-medphabespi-20-2023/

EIC - The European Innovation Council